Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.
Key Financial Performance
Total Revenue $16.6 million for the quarter, a decrease of approximately 3% year-over-year. The decline was due to the absence of data revenue ($4.5 million in the prior year period) from the nascent data platform.
Core Study Revenue $16.6 million for the quarter, an increase of approximately 32% year-over-year. This growth was driven by strong study execution and conversion of previously booked work.
Data Revenue $0 for the quarter, compared to $4.5 million in the prior year period. The decline reflects the variability of data revenue at this stage of platform development.
Gross Margin 47% for the quarter, compared to 61% in the prior year period. The decline was due to over $2 million in outsourced laboratory work costs and the absence of prior year data license transaction benefits.
Cost of Sales $8.8 million for the quarter, compared to $6.6 million in the prior year period. The increase was primarily due to outsourced laboratory work costs related to radiolabeling workflows.
Operating Expenses $7.2 million for the quarter, compared to $5.3 million in the prior year period. The increase was driven by investments in R&D, sales and marketing, and IT infrastructure.
Adjusted EBITDA $575,000 for the quarter, marking the third consecutive quarter of positive adjusted EBITDA. This was supported by revenue performance and operating discipline.
GAAP Loss from Operations Approximately $275,000 for the quarter. This reflects the impact of increased operating expenses and cost of sales.
Net Cash Used in Operating Activities $1.4 million for the quarter. This was primarily driven by changes in working capital, including a decrease in deferred revenue.
Cash Balance $7.1 million at the end of the quarter, with no debt. The cash balance remains within the projected range for the quarter.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Data Platform: Momentum is building with new deals closed during the quarter and additional revenue expected in Q4. A six-figure data deal was closed, and traction with smaller transactions is growing. The large data deal from Q3 fiscal '25 is progressing with incremental revenue expected in Q4.
Corellia (Target Discovery Subsidiary): Continues to generate attractive data and positive feedback from potential venture capital funding partners and licensing counterparts. External funding discussions are ongoing, with potential to redeploy EBITDA investments if successful.
Radiopharmaceutical Capability: Growing capability enhances competitive positioning in the market.
Services Revenue: Achieved record services revenue of $16.6 million, reflecting 32% growth year-over-year in core study revenue. This was supported by strong study execution and conversion of previously booked work.
Operational Efficiency: Growth achieved without material additions to headcount, demonstrating operating leverage and margin expansion potential.
Cost Management: Outsourced laboratory work costs impacted gross margins, but bringing this work in-house is expected to improve margins.
Investment in Growth Drivers: Continued investment in data platform, Corellia, and radiopharmaceutical capabilities while maintaining positive adjusted EBITDA.
Long-term Growth Strategy: Focus on building a diversified company with interrelated growth vectors in services, data, and therapeutics to maximize shareholder value.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Quarterly revenue fluctuation: Quarterly revenue can fluctuate depending on the timing of study progression and completion, which introduces unpredictability in financial performance.
Year-over-year revenue decline: A slight decline in year-over-year revenue was noted due to the absence of a large data deal closed in the prior year, highlighting dependency on large deals for revenue growth.
Data revenue variability: Data revenue remains inconsistent and nascent, with no data revenue recognized this quarter, which could impact overall revenue stability.
Gross margin pressure: Gross margin declined to 47% from 61% in the prior year, partly due to $2 million in outsourced laboratory work. This indicates cost inefficiencies that need to be addressed.
Increased operating expenses: Operating expenses rose to $7.2 million from $5.3 million in the prior year, driven by investments in R&D, sales, marketing, and IT infrastructure, which could pressure short-term profitability.
Biotech funding environment: The challenging biotech funding environment may delay external financing for Corellia, potentially impacting its development and the company's ability to redeploy funds.
Cash flow concerns: Net cash used in operating activities was $1.4 million, and the company ended the quarter with $7.1 million in cash, which may limit flexibility for future investments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue normalization: Looking ahead, revenue is expected to normalize as studies progress through various stages. However, the underlying demand for services remains healthy, and the company is focused on expanding the pipeline of future work through increased commercial engagement.
Full-year financial outlook: The company remains on track for full-year revenue growth and positive adjusted EBITDA, while continuing to invest in its data business and Corellia subsidiary.
Data business momentum: The company expects to recognize revenue from a six-figure data deal in Q4 and anticipates incremental revenue from a large data deal announced in Q3 of fiscal '25. The data business is expected to show more meaningful acceleration in fiscal 2027 and fiscal 2028.
Corellia funding and growth: The company has included funding for Corellia in its fiscal 2027 budgeting assumptions. If external funding is secured, the EBITDA currently invested in Corellia will be redeployed toward other growth initiatives or flow through to the bottom line.
Gross margin improvement: As outsourced laboratory work is brought in-house, costs are expected to decline, leading to improved gross margins. At current revenue levels, internalizing this work would result in gross margins exceeding 50%.
Long-term growth and profitability: The company believes that current investments in data, radiopharmaceutical capabilities, and Corellia position it for stronger growth and expanding profitability in the years ahead.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Were there any questions from the lines during the Q&A session?
A:No, there were no questions from the lines during the Q&A session.
Q:Review of Unclear Management Responses
A:There were no questions asked during the session, so management did not avoid giving any direct answers or provide unclear responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bank differentiator
CEO Champions
CFO today
Champions share
Champions today
Corellia budgeting
Corellia dilution
Corellia discussion
Corellia point
Customer engagement
Oncology progress
PDX Bank
SEC takeaway
ability timing
acceleration update
addition leverage
afternoon CEO
allocation future
annotation tumor
assumption funding
backlog quarter
balance investment
bank service
basis
deal
detail
driver
funding Corellia
momentum
opportunity Corellia
potential
record service
service platform
subsidiary
track
traction
work
year
CSBR Transcript
Champions Oncology, Inc. (CSBR) Q3 2026 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: a decline in year-over-year revenue and gross margins, and increased operating expenses, are concerning. However, positive adjusted EBITDA, growth in core study revenue, and strategic investments in data and radiopharmaceuticals offer optimism. The absence of Q&A questions limits further sentiment insight. Given these mixed factors, the stock price is likely to remain stable over the next two weeks.
Champions Oncology, Inc. (CSBR) Q2 2026 Earnings Call Transcript
Positive12-15
The earnings call highlights several positives: revenue growth, margin expansion, and a strong cash position. Gross margins improved significantly, and the company anticipates further expansion. Although operating expenses increased due to strategic investments, the funding environment is improving, and cancellations have returned to historic levels. The Q&A session revealed optimism about market recovery and strategic hires to boost the data business. Despite some uncertainties, the overall sentiment is positive, with expectations of continued growth and profitability, likely resulting in a stock price increase of 2% to 8%.
Champions Oncology, Inc. (CSBR) Q1 2026 Earnings Call Transcript
Unknown9-15
The earnings call reveals mixed signals: stable revenue with signs of recovery but increased costs leading to a loss. The data business shows potential growth, but management's vague responses in the Q&A about future opportunities and revenue guidance create uncertainty. Operational inefficiencies and increased expenses further complicate the outlook. Despite optimism in some areas, the lack of clear guidance and current financial strain suggest a neutral stock movement in the short term.
Champions Oncology (CSBR) Q4 2025 Earnings Call Transcript
Unknown7-25
The earnings call presents mixed signals. Financial performance shows positive trends with increased annual revenue and improved EBITDA, but quarterly metrics are weak, with declining Q4 revenue and margins. Product development shows promise in high-margin areas like radiopharmaceuticals, yet the Q&A reveals uncertainties in data licensing and partnerships. The company's cautious optimism about fiscal '26 and improved cash position are positives, but lack of specific guidance and rising expenses temper enthusiasm. Overall, the mixed financials and unclear growth prospects suggest a neutral short-term stock price reaction.
CSBR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
